Feb 2 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES POSITIVE RESULTS OF A PHASE 1A
PHARMACOKINETIC
STUDY FOR INFLAMMATORY BOWEL DISEASE/PRIMARY SCLEROSING
CHOLANGITIS (IBD/PSC) EVALUATING DELIVERY OF ORAL BX002 PHAGE
THERAPY
    * BIOMX - BX002 DEMONSTRATED SAFETY AND TOLERABILITY WITH
SUCCESSFUL DELIVERY OF A HIGH CONCENTRATION OF VIABLE PHAGE TO
LOWER GASTROINTESTINAL TRACT
    * BIOMX INC - EFFICACY RESULTS IN REDUCTION OF TARGET
BACTERIA
EXPECTED BY MID-2022 FROM PLANNED PHASE 1B/2A STUDY
    * BIOMX INC - IN PHASE 1A STUDY, BX002 WAS DEMONSTRATED TO
BE SAFE
AND WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS

Source text for Eikon:  ID:nBwc1x0X1a 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))